Lepodisiran
Sponsors
Eli Lilly & Co., Eli Lilly and Company
Conditions
AtherosclerosisAtherosclerotic Cardiovascular Disease
Elevated lp(a)Cardiovascular DiseasesHealthyLipoprotein(a)Liver Dysfunction
Phase 1
Phase 3
J3L-MC-EZEF:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)
Active, not recruitingCTIS2023-509190-23-00
Start: 2024-09-03Target: 4175Updated: 2025-11-21
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
RecruitingNCT07613294
Start: 2026-06-01End: 2029-12-01Target: 252Updated: 2026-09-08
J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
Not yet recruitingCTIS2025-524858-34-00
Target: 145Updated: 2026-07-31